Why the study?
Bleeding complications and nonadherence limit systemic anticoagulation, creating a need to review left atrial appendage occlusion as a nonpharmacologic strategy for stroke prevention in nonvalvular AF.
Do left atrial appendage occlusion devices prevent stroke in patients with nonvalvular atrial fibrillation?
Do left atrial appendage occlusion devices prevent stroke in patients with nonvalvular atrial fibrillation?
This review summarizes the history, clinical trials, and regulatory milestones of left atrial appendage occlusion devices as a nonpharmacologic alternative to systemic anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
Updated LAAO reference for AF stroke prevention; extends prior syntheses with recent trials and FDA milestones.
The majority of embolic strokes in patients with nonvalvular atrial fibrillation are caused by thrombi in the left atrial appendage. It is projected that strokes related to atrial fibrillation will markedly increase in the future unless effective mitigation strategies are implemented. Systemic anticoagulation has been known to be highly effective in reducing stroke risk in patients with atrial fibrillation. However, bleeding complications and nonadherence are barriers to effective anticoagulation therapy. Surgical and percutaneous left atrial appendage occlusion devices are nonpharmacologic strategies to mitigate the challenges of drug therapy. We present a contemporary review of left atrial appendage occlusion for stroke prevention in nonvalvular atrial fibrillation. A thorough review of the history of surgical and percutaneous left atrial appendage occlusion devices, recent trials, and US Food and Drug Administration milestones of current left atrial appendage occlusion devices are discussed.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: